abstract: BACKGROUND: Muscle weakness and @entity2 are common symptoms in @entity1 ( @entity1 ). Green tea catechins such as (-)epigallocatechin-3-gallate (EGCG) are known to improve energy metabolism at rest and during exercise. OBJECTIVE: We tested the hypothesis that EGCG improves energy metabolism and substrate utilization in @entity0 with @entity1 . DESIGN: Eighteen @entity0 (8 @entity0 ) with relapsing-remitting @entity1 (expanded disability status scale score <4.5, all receiving glatiramer acetate) participated in this randomized, double-blind, placebo-controlled, crossover trial at a clinical research center. All @entity0 received EGCG (600 mg/d) and placebo over 12 wk (4-wk washout in between). After each intervention, fasting and postprandial energy expenditure (EE), as well as fat oxidation (FAOx) and carbohydrate oxidation (CHOx) rates, were measured either at rest or during 40 min of exercise (0.5 W/kg). At rest, blood samples and microdialysates from adipose tissue and skeletal muscle were also taken. RESULTS: At rest, postprandial EE and CHOx, as well as adipose tissue perfusion and glucose supply, were significantly lower in @entity0 but higher in @entity0 receiving EGCG compared with placebo. During exercise, postprandial EE was lower after EGCG than after placebo, indicating an increased working efficiency ( @entity0 > @entity0 ). After placebo, exercise EE was mainly fueled by FAOx in both @entity0 and @entity0 . After EGCG, there was a shift to a higher and more stable CHOx during exercise in @entity0 but not in @entity0 . CONCLUSIONS: Our data indicate that EGCG given to @entity0 with @entity1 over 12 wk improves muscle metabolism during moderate exercise to a greater extent in @entity0 than in @entity0 , possibly because of sex-specific effects on autonomic and endocrine control. This trial was registered at clinicaltrials.gov as NCT01417312.

title: Metabolic response to epigallocatechin-3-gallate in relapsing-remitting XXXX : a randomized clinical trial.

answer: @entity1


abstract: BACKGROUND: Whether vitamin supplements decrease @entity1 risk is controversial. Previous reports did not all take confounding fully into account, either by randomization or by extensive adjustment. OBJECTIVE: The aim of our study was to determine whether vitamin supplementation decreases the risk of @entity1 . DESIGN: A large case-control study included 2506 @entity0 with @entity1 , 2506 partner controls, and 2684 random-digit dialing (RDD) controls. When @entity0 were compared with RDD controls, unconditional logistic regression was used to calculate ORs with 95% CIs. When @entity0 were compared with partner controls, conditional logistic regression was used, providing further adjustment for unmeasured confounding. RESULTS: Vitamin use yielded a 37% lower risk of @entity1 than no vitamin use (OR: 0.63; 95% CI: 0.57, 0.70) when comparing @entity0 with RDD controls. Adjustment for several putative confounders did not change the estimate (OR: 0.68; 95% CI: 0.61, 0.77). The fully adjusted ORs for vitamin A, vitamin B-6, vitamin B-12, folic acid, vitamin C, vitamin D, vitamin E, and multivitamin use were in the same range. However, when @entity0 were compared with partner controls, ORs attenuated to unity. Results were similar for provoked and unprovoked events, as well as for @entity2 and @entity3 . CONCLUSIONS: After extensive adjustments, vitamin supplementation was no longer associated with a decreased risk of @entity1 in this study. Previous positive results may have been spurious as a result of uncontrolled confounding.

title: Vitamin supplementation on the risk of XXXX : results from the MEGA case-control study.

answer: @entity1


abstract: BACKGROUND: @entity1 maintenance treatment (MMT) reduces the harms of @entity3 and is being rapidly scaled-up in China. This study evaluated the real-world implementation of MMT system in Wuhan, China. METHODS: Data extracted from electronic medical records collected in 2010 on 8811 @entity0 were used to compute for each @entity0 indices of the prescribed and consumed daily @entity1 doses, an adherence index, dose adjustments following missed doses, the rates of opiate positive urine tests, self-reported drug use, @entity2 ( @entity2 ), and the duration of MMT exposure. FINDINGS: The modal daily doses prescribed were 60mg and above for 68.5% of @entity0 . Adherence was variable: 51% of @entity0 attended less than 60% and 26% attended 80-100% of their treatment days; and @entity0 with long MMT exposure had significantly higher adherence rates than @entity0 with short MMT exposure. The differences between doses dispensed immediately before and after the interruption in dosing days ranged from 0 to 7mg, independently of the length of the interruption or the prescribed dosing level. The overall rate of opiate positive tests was 20%; 45% of @entity0 had at least one opiate positive test; 29% reported past month drug use and 53% of them reported past month @entity2 . Adherence and MMT exposure duration correlated significantly with the proportion of opiate negative urine tests (r=0.355, p<0.001; r=0.351, p<0.001, respectively). Treatment for males and females was comparable. CONCLUSIONS: Provision of safe @entity1 dosing after absences and improving daily attendance are identified as priority improvement areas.

title: Evaluation of an implementation of XXXX maintenance treatment in China.

answer: @entity1


abstract: OBJECTIVES: To investigate in-vivo @entity1 branching from the anterior communicating artery (ACoA) using @entity2 ( @entity2 ) magnetic resonance angiography (MRA) at 7 Tesla. METHODS: Seventy-five subjects, including 15 healthy volunteers and 60 @entity0 , were included in this prospective study. Three raters characterized branches from ACoA in maximum intensity projections of @entity2 MRA at 7 Tesla acquired with 0.22   *   0.22   *   0.41  mm(3) resolution. Furthermore, course patterns and anatomical features of the subcallosal artery (maximum diameter, length, and branching angle from ACoA) were measured. RESULTS: Branches from the anterior communicating artery were visualized in 63 of 74 (85.1  %) subjects and were identified as the subcallosal artery (93.7  %) and the @entity3 (6.3  %). The course of the subcallosal artery was classified into 3 groups; C-shaped (55.9  %), straight (16.9  %), and S-shaped (27.2  %). There was a significant difference between the branching angles of C-shaped and straight (p   <   0.0001), between C-shaped and S-shaped (p   <   0.0001), as well as between straight and S-shaped (p   =   0.0113) course patterns. CONCLUSIONS: High-resolution in-vivo 7 T @entity2 MRA can delineate the @entity1 . Three main variants of course patterns and branching angles from ACoA could be identified. KEY POINTS:     In-vivo 7 Tesla @entity2 MRA can delineate the subcallosal artery microanatomy     Three distinct course patterns of the subcallosal artery were identified     Branching angles from ACoA significantly differed between subcallosal artery course patterns.

title: XXXX : an in-vivo 7 T magnetic resonance angiography study.

answer: @entity1


abstract: INTRODUCTION: The Sino-Nasal Outcome Test 22 (SNOT-22) is an important tool in assessing the quality of life (QoL) of @entity0 with chronic rhinosinusitis with a validated version in Brazil. The @entity3 ( @entity3 ) represents most of the cases of @entity3 (85-90%) and belongs to the group of chronic rhinosinusitis. It is a chronic inflammatory disease that impacts the QoL of @entity0 , not only causing localized symptoms, but also resulting in a general malaise. The standard treatments (corticosteroids and nasal endoscopic surgery) lead to partial control of symptoms, but relapses are frequent. @entity6 acting as an immunomodulator is a promising tool for more effective control of this disease. Studies are still lacking to assess the real impact on the QoL in @entity0 treated with @entity5 . OBJECTIVE: To evaluate the improvement of QL, evaluated using SNOT-22, in @entity0 with PNSE treated with immunomodulatory dose @entity4 . METHODS: This is a paired experimental study in @entity0 with @entity3 . Comparison of pre-treatment and post-treatment with @entity4 was performed. @entity0 completed the SNOT-22 questionnaire before the start of treatment and returned for evaluation after eight weeks of treatment. @entity4 was prescribed at a dose of 500mg, orally, three times a week, for 8 weeks. RESULTS: SNOT-22 score decreased 20.3 points on average. There was a significant decrease in the SNOT-22 (difference greater than 14 points) in 19 @entity0 (57.6%). There was no significant difference in improvement in SNOT in subgroups with or without @entity2 / @entity1 intolerance. CONCLUSION: @entity4 resulted in significant improvement of QoL, assessed by SNOT-22, in the studied population.

title: Evaluation of improved quality of life with @entity4 in the treatment of XXXX .

answer: @entity3


abstract: INTRODUCTION: The Sino-Nasal Outcome Test 22 (SNOT-22) is an important tool in assessing the quality of life (QoL) of @entity0 with chronic rhinosinusitis with a validated version in Brazil. The @entity3 ( @entity3 ) represents most of the cases of @entity3 (85-90%) and belongs to the group of chronic rhinosinusitis. It is a chronic inflammatory disease that impacts the QoL of @entity0 , not only causing localized symptoms, but also resulting in a general malaise. The standard treatments (corticosteroids and nasal endoscopic surgery) lead to partial control of symptoms, but relapses are frequent. @entity6 acting as an immunomodulator is a promising tool for more effective control of this disease. Studies are still lacking to assess the real impact on the QoL in @entity0 treated with @entity5 . OBJECTIVE: To evaluate the improvement of QL, evaluated using SNOT-22, in @entity0 with PNSE treated with immunomodulatory dose @entity4 . METHODS: This is a paired experimental study in @entity0 with @entity3 . Comparison of pre-treatment and post-treatment with @entity4 was performed. @entity0 completed the SNOT-22 questionnaire before the start of treatment and returned for evaluation after eight weeks of treatment. @entity4 was prescribed at a dose of 500mg, orally, three times a week, for 8 weeks. RESULTS: SNOT-22 score decreased 20.3 points on average. There was a significant decrease in the SNOT-22 (difference greater than 14 points) in 19 @entity0 (57.6%). There was no significant difference in improvement in SNOT in subgroups with or without @entity2 / @entity1 intolerance. CONCLUSION: @entity4 resulted in significant improvement of QoL, assessed by SNOT-22, in the studied population.

title: Evaluation of improved quality of life with XXXX in the treatment of @entity3 .

answer: @entity4


abstract: BACKGROUND: @entity4 nanoparticles (AgNPs) possess unique physical, chemical, and biological properties. AgNPs have been increasingly used as anticancer, antiangiogenic, and antibacterial agents for the treatment of @entity5 in open wounds as well as in ointments, bandages, and wound dressings. The present study aimed to investigate the effects of two different sizes of AgNPs (10 nm and 20 nm) in male somatic Leydig (TM3) and Sertoli (TM4) cells and spermatogonial stem cells (SSCs). METHODS: Here, we demonstrate a green and simple method for the synthesis of AgNPs using @entity8 culture supernatants. The synthesized AgNPs were characterized using ultraviolet and visible absorption spectroscopy, X-ray diffraction, Fourier transform infrared spectroscopy, and transmission electron microscopy (TEM). The @entity2 of the synthesized AgNPs was evaluated by the effects on cell viability, metabolic activity, oxidative stress, apoptosis, and expression of genes encoding steroidogenic and tight junction proteins. RESULTS: AgNPs inhibited the viability and proliferation of TM3 and TM4 cells in a dose- and size-dependent manner by damaging cell membranes and inducing the generation of reactive @entity0 species, which in turn affected SSC growth on TM3 and TM4 as feeder cells. Small AgNPs (10 nm) were more cytotoxic than medium-sized nanoparticles (20 nm). TEM revealed the presence of AgNPs in the cell cytoplasm and nucleus, and detected @entity6 and enhanced formation of autosomes and autolysosomes in the AgNP-treated cells. Flow cytometry analysis using Annexin V/ @entity7 staining showed massive cell death by apoptosis or @entity1 . Real-time polymerase chain reaction and western blot analyses indicated that in TM3 and TM4 cells, AgNPs activated the p53, p38, and pErk1/2 signaling pathways and significantly downregulated the expression of genes related to @entity3 synthesis (TM3) and tight junctions (TM4). Furthermore, the exposure of TM3 and TM4 cells to AgNPs inhibited proliferation and self-renewal of SSCs. CONCLUSION: Our results suggest that AgNPs exhibit size-dependent nanoreprotoxicity in male somatic cells and SSCs, strongly suggesting that applications of AgNPs in commercial products must be carefully evaluated. Further studies of AgNPs-induced nanoreprotoxicity in animal models are required.

title: Differential nanoreprotoxicity of XXXX nanoparticles in male somatic cells and spermatogonial stem cells.

answer: @entity4


abstract: Previous studies of the TCR alpha chain gene have located promoter elements 5' to the start of the various V alpha genes. The only fully characterized enhancer for the entire alpha chain gene (V, J and C genes) has been located approximately 3 kb from the 3' end of C alpha. We now report the existence of additional regulatory elements located in the introns of several @entity0 V alpha genes (V alpha 1, V alpha 3 and V alpha B6.2.16). In the case of V alpha 1, this element appears to be a promoter with bidirectional activity that is not T cell specific. Interestingly, upstream of the promoter in the antisense strand, an open reading frame has been found that codes for a small molecular weight protein (approximately 60 @entity5 ) that contains a @entity4 -rich region and a @entity2 - @entity6 motif that has homology to @entity7 (the @entity7 gene product). A rabbit antiserum made against this sequence has confirmed its existence by Western blot and immunoprecipitation. Thus this V alpha 1 intronic promoter has the potential not only to induce the formation of a truncated V alpha 1 gene product, but also regulates the expression of a small molecular weight protein that may be involved in lymphocyte antigen receptor signaling. The activity of this promoter is regulated by changes in intracellular @entity1 . In the presence of @entity3 the promoter is down-regulated in the sense direction and its activity is enhanced in the antisense direction. This result suggests that this promoter can act differentially to produce two very different gene products. The bidirectional V alpha 1 promoter appears to be the first in the Ig superfamily to induce potentially functional proteins in both directions.

title: Evidence for a XXXX regulated, bidirectional intronic promoter in the @entity0 TCR V alpha 1 gene.

answer: @entity1


abstract: Previous studies of the TCR alpha chain gene have located promoter elements 5' to the start of the various V alpha genes. The only fully characterized enhancer for the entire alpha chain gene (V, J and C genes) has been located approximately 3 kb from the 3' end of C alpha. We now report the existence of additional regulatory elements located in the introns of several @entity0 V alpha genes (V alpha 1, V alpha 3 and V alpha B6.2.16). In the case of V alpha 1, this element appears to be a promoter with bidirectional activity that is not T cell specific. Interestingly, upstream of the promoter in the antisense strand, an open reading frame has been found that codes for a small molecular weight protein (approximately 60 @entity5 ) that contains a @entity4 -rich region and a @entity2 - @entity6 motif that has homology to @entity7 (the @entity7 gene product). A rabbit antiserum made against this sequence has confirmed its existence by Western blot and immunoprecipitation. Thus this V alpha 1 intronic promoter has the potential not only to induce the formation of a truncated V alpha 1 gene product, but also regulates the expression of a small molecular weight protein that may be involved in lymphocyte antigen receptor signaling. The activity of this promoter is regulated by changes in intracellular @entity1 . In the presence of @entity3 the promoter is down-regulated in the sense direction and its activity is enhanced in the antisense direction. This result suggests that this promoter can act differentially to produce two very different gene products. The bidirectional V alpha 1 promoter appears to be the first in the Ig superfamily to induce potentially functional proteins in both directions.

title: Evidence for a @entity1 regulated, bidirectional intronic promoter in the XXXX TCR V alpha 1 gene.

answer: @entity0


abstract: PURPOSE: Rates of late @entity1 are higher for salvage treatment of local recurrence after prior radiotherapy. We present our experience with salvage prostate brachytherapy (BT) for local recurrence after definitive external beam radiotherapy with attention to the relationship between dose and late @entity1 . METHODS AND MATERIALS: From 2005 to 2012, 18 @entity0 with biopsy proven locally recurrent @entity2 and negative staging received low-dose-rate BT with a prescribed dose of 130-144  Gy. @entity1 were graded using Common Terminology Criteria for Adverse Events, version 3.0. RESULTS: Median followup is 31.5  months (range, 12-104). International Prostate Symptom Scores peaked at 3  months (median, 21/35), returning to baseline by 24  months. Urinary catheterization rate was 33% (median duration, 14  days; range, 1-90  days). Late Grade 3/4 genitourinary @entity1 occurred in 1 @entity0 each, one of whom also had Grade 3 late @entity3 ; urethral strictures developed in three others. These 5 @entity0 with late @entity1 had higher dose to the prostate (isodose enclosing 90% [D90] median, 151 Gy; range, 135-185 Gy) compared with those without late complications (median, 134  Gy; range, 105-165; p < 0.04). Acute @entity3 Grade <3 occurred in 44%. Four @entity0 (22%) experienced biochemical failure. CONCLUSION: Salvage low-dose-rate prostate BT can provide durable biochemical control. Care should be taken to select @entity0 with higher likelihood of organ-confined disease. The goal of planning should be to treat the recurrent disease to an adequate dose with careful attention to maintain a conservative D90.

title: Salvage low-dose-rate permanent seed brachytherapy for locally recurrent @entity2 : Association between dose and late XXXX .

answer: @entity1


abstract: PURPOSE: Rates of late @entity1 are higher for salvage treatment of local recurrence after prior radiotherapy. We present our experience with salvage prostate brachytherapy (BT) for local recurrence after definitive external beam radiotherapy with attention to the relationship between dose and late @entity1 . METHODS AND MATERIALS: From 2005 to 2012, 18 @entity0 with biopsy proven locally recurrent @entity2 and negative staging received low-dose-rate BT with a prescribed dose of 130-144  Gy. @entity1 were graded using Common Terminology Criteria for Adverse Events, version 3.0. RESULTS: Median followup is 31.5  months (range, 12-104). International Prostate Symptom Scores peaked at 3  months (median, 21/35), returning to baseline by 24  months. Urinary catheterization rate was 33% (median duration, 14  days; range, 1-90  days). Late Grade 3/4 genitourinary @entity1 occurred in 1 @entity0 each, one of whom also had Grade 3 late @entity3 ; urethral strictures developed in three others. These 5 @entity0 with late @entity1 had higher dose to the prostate (isodose enclosing 90% [D90] median, 151 Gy; range, 135-185 Gy) compared with those without late complications (median, 134  Gy; range, 105-165; p < 0.04). Acute @entity3 Grade <3 occurred in 44%. Four @entity0 (22%) experienced biochemical failure. CONCLUSION: Salvage low-dose-rate prostate BT can provide durable biochemical control. Care should be taken to select @entity0 with higher likelihood of organ-confined disease. The goal of planning should be to treat the recurrent disease to an adequate dose with careful attention to maintain a conservative D90.

title: Salvage low-dose-rate permanent seed brachytherapy for locally recurrent XXXX : Association between dose and late @entity1 .

answer: @entity2


abstract: INTRODUCTION: Mild @entity2 is common in nondemented @entity3 @entity0 ( @entity6 ) and is considered as a risk factor for @entity4 ( @entity8 ). Recently, the @entity5 ( @entity5 ) published guidelines for @entity6 , although the studies available are still limited. The aim of this work was to characterize @entity6 and its progression to @entity4 . Moreover, the study variables could be considered as predictors for the progression of @entity2 . METHOD: The study included 43 @entity0 with idiopathic @entity6 (mean age = 59.19 years, SD = 9.64) and 20 healthy and neurologically normal controls (mean age = 60.85 years, SD = 12.26). The criteria proposed by the @entity5 Task Force were applied for the @entity6 diagnosis. Follow-up assessments were conducted within six to eight years after the diagnosis of @entity6 . RESULTS: The results showed that 60.5% of the @entity0 were diagnosed with @entity6 when a comprehensive assessment was performed ( @entity5 criteria Level 2), while 23.3% of the @entity0 met MCI criteria when a brief assessment was used ( @entity5 criteria Level 1). Multiple domain impairment was the most frequent impairment (96.2%). A total of 42.3% of @entity6 @entity0 had @entity4 in the follow-up study. Logistic regression showed that the Hoehn and Yahr stage and education significantly contributed to the prediction of @entity6 . Moreover, the Hoehn and Yahr stage and memory domain significantly contributed to the prediction of @entity4 . CONCLUSIONS: The results of the study: (a) provide relevant data about the process of validation of the @entity5 , (b) reinforce the hypothesis that @entity6 is more frequent than previous studies showed without applying @entity5 criteria, and (c) confirm that @entity6 is a risk factor for the onset of @entity4 . Finally, the study shows that @entity1 , educational level and @entity7 were predictors for the progression of @entity2 .

title: Mild @entity2 in XXXX : Diagnosis and progression to @entity4 .

answer: @entity3


abstract: INTRODUCTION: Mild @entity2 is common in nondemented @entity3 @entity0 ( @entity6 ) and is considered as a risk factor for @entity4 ( @entity8 ). Recently, the @entity5 ( @entity5 ) published guidelines for @entity6 , although the studies available are still limited. The aim of this work was to characterize @entity6 and its progression to @entity4 . Moreover, the study variables could be considered as predictors for the progression of @entity2 . METHOD: The study included 43 @entity0 with idiopathic @entity6 (mean age = 59.19 years, SD = 9.64) and 20 healthy and neurologically normal controls (mean age = 60.85 years, SD = 12.26). The criteria proposed by the @entity5 Task Force were applied for the @entity6 diagnosis. Follow-up assessments were conducted within six to eight years after the diagnosis of @entity6 . RESULTS: The results showed that 60.5% of the @entity0 were diagnosed with @entity6 when a comprehensive assessment was performed ( @entity5 criteria Level 2), while 23.3% of the @entity0 met MCI criteria when a brief assessment was used ( @entity5 criteria Level 1). Multiple domain impairment was the most frequent impairment (96.2%). A total of 42.3% of @entity6 @entity0 had @entity4 in the follow-up study. Logistic regression showed that the Hoehn and Yahr stage and education significantly contributed to the prediction of @entity6 . Moreover, the Hoehn and Yahr stage and memory domain significantly contributed to the prediction of @entity4 . CONCLUSIONS: The results of the study: (a) provide relevant data about the process of validation of the @entity5 , (b) reinforce the hypothesis that @entity6 is more frequent than previous studies showed without applying @entity5 criteria, and (c) confirm that @entity6 is a risk factor for the onset of @entity4 . Finally, the study shows that @entity1 , educational level and @entity7 were predictors for the progression of @entity2 .

title: Mild @entity2 in @entity3 : Diagnosis and progression to XXXX .

answer: @entity4


abstract: INTRODUCTION: Mild @entity2 is common in nondemented @entity3 @entity0 ( @entity6 ) and is considered as a risk factor for @entity4 ( @entity8 ). Recently, the @entity5 ( @entity5 ) published guidelines for @entity6 , although the studies available are still limited. The aim of this work was to characterize @entity6 and its progression to @entity4 . Moreover, the study variables could be considered as predictors for the progression of @entity2 . METHOD: The study included 43 @entity0 with idiopathic @entity6 (mean age = 59.19 years, SD = 9.64) and 20 healthy and neurologically normal controls (mean age = 60.85 years, SD = 12.26). The criteria proposed by the @entity5 Task Force were applied for the @entity6 diagnosis. Follow-up assessments were conducted within six to eight years after the diagnosis of @entity6 . RESULTS: The results showed that 60.5% of the @entity0 were diagnosed with @entity6 when a comprehensive assessment was performed ( @entity5 criteria Level 2), while 23.3% of the @entity0 met MCI criteria when a brief assessment was used ( @entity5 criteria Level 1). Multiple domain impairment was the most frequent impairment (96.2%). A total of 42.3% of @entity6 @entity0 had @entity4 in the follow-up study. Logistic regression showed that the Hoehn and Yahr stage and education significantly contributed to the prediction of @entity6 . Moreover, the Hoehn and Yahr stage and memory domain significantly contributed to the prediction of @entity4 . CONCLUSIONS: The results of the study: (a) provide relevant data about the process of validation of the @entity5 , (b) reinforce the hypothesis that @entity6 is more frequent than previous studies showed without applying @entity5 criteria, and (c) confirm that @entity6 is a risk factor for the onset of @entity4 . Finally, the study shows that @entity1 , educational level and @entity7 were predictors for the progression of @entity2 .

title: Mild XXXX in @entity3 : Diagnosis and progression to @entity4 .

answer: @entity2


abstract: A 81-year-old @entity0 confined to full bed rest due to the effects of a @entity3 7 years prior, was brought to our hospital with acute @entity7 in late April 2013. After PTGBD, her condition improved and she was discharged in early June. However, she was urgently hospitalized at the beginning of August with melena and a fever. A detailed examination revealed @entity5 , which was resolved with a course of antibiotics. A colonoscopy, conducted to find the cause of the melena, revealed a circumferential type 2 @entity2 in the ascending colon, and a fiberscope was unable to pass through the @entity4 . A biopsy confirmed a diagnosis of @entity6 . Using abdominal computed tomography, thickening of the ascending colon wall, suggesting infiltration to the periphery, was visible. The adjacent lymph nodes were enlarged, but there were no clear signs of liver @entity1 . @entity8 was suspected due to the presence of ascitic fluid. Considering the overall condition of the @entity0 , surgery was not performed, and colonic stent was not placed due to the proximity of the @entity4 to the ileocecal valve. The @entity0 's family chose best supportive care. The @entity0 's condition worsened and she died 3 months after leaving the hospital.

title: [A case of ascending colon signet-ring cell careinoma discovered after treatment for acute XXXX ].

answer: @entity7


abstract: A 7 1-year-old @entity0 presented to our hospital with @entity7 and @entity4 . Computed tomography of the abdomen and colonoscopy revealed @entity1 of the transverse colon. The biopsy specimen indicated a highly differentiated @entity3 . The @entity0 underwent extended right hemicolectomy with regional lymph node dissection. Pathological examination showed a @entity10 (NEC)with concurrent @entity5 and regional lymph node metastases of the NEC and @entity3 . The histopathological examination confirmed a diagnosis of mixed @entity2 (MANEC)in accordance with the 2010WHO Classification of Tumors of the Digestive System. Liver and lung metastases were identified 8 months after the surgery. We administered chemotherapy including @entity9 , @entity11 , and @entity6 (mFOLFOX)plus bevacizumab, with limited therapeutic effect, as the disease progressed despite treatment. The @entity0 chose best supportive care 13 months after the surgery. Several studies have reported that most @entity0 with @entity8 , including MANEC, experience relapse within 1 year after surgery, and few @entity0 remain disease-free for long periods after surgery. The optimal strategy for the management of MANEC is variable owing to its rarity; only 2 cases of MANEC in the colon, including the present case, have been reported in Japan. It is thus important to gather more evidence on this disease and its management.

title: [A case of mixed XXXX of the transverse colon].

answer: @entity2


abstract: An 80-year-old @entity0 was treated with low anterior resection and D3 lymph node dissection for @entity3 in August 2007. Pathological diagnosis was a @entity2 23*22mm in size with muscularis propria invasion, ly1, v0, n1(No. 251[1/12]). Partial hepatectomy was performed for liver @entity1 in March 2010 and September 2011. In June 2013, an @entity2 of 17mm in diameter was detected between the inferior vena cava and the stomach using abdominal ultrasonography. The @entity2 was diagnosed as pancreatic head lymph node @entity1 using abdominal enhanced computed tomography(CT), magnetic resonance cholangiopancreatography(MRCP), and positron emission tomography(PET); fluorodeoxyglucose (FDG)uptake was noted at the site of the @entity2 , but not at other parts of the body. Curative resection was the chosen treatment option. Open surgery was performed in September 2013, and a @entity2 30mm in diameter located at the ventral side of the inferior vena cava, lateral side of the portal vein, and cranial side of duodenum was resected. No surrounding tissue infiltration was found. Pathological analysis of the resected specimen indicated lymph node @entity1 of the @entity3 . The @entity0 has been disease free for 9 months after surgery.

title: [A case of resection of pancreatic head lymph node XXXX of @entity3 ].

answer: @entity1


abstract: An 80-year-old @entity0 was treated with low anterior resection and D3 lymph node dissection for @entity3 in August 2007. Pathological diagnosis was a @entity2 23*22mm in size with muscularis propria invasion, ly1, v0, n1(No. 251[1/12]). Partial hepatectomy was performed for liver @entity1 in March 2010 and September 2011. In June 2013, an @entity2 of 17mm in diameter was detected between the inferior vena cava and the stomach using abdominal ultrasonography. The @entity2 was diagnosed as pancreatic head lymph node @entity1 using abdominal enhanced computed tomography(CT), magnetic resonance cholangiopancreatography(MRCP), and positron emission tomography(PET); fluorodeoxyglucose (FDG)uptake was noted at the site of the @entity2 , but not at other parts of the body. Curative resection was the chosen treatment option. Open surgery was performed in September 2013, and a @entity2 30mm in diameter located at the ventral side of the inferior vena cava, lateral side of the portal vein, and cranial side of duodenum was resected. No surrounding tissue infiltration was found. Pathological analysis of the resected specimen indicated lymph node @entity1 of the @entity3 . The @entity0 has been disease free for 9 months after surgery.

title: [A case of resection of pancreatic head lymph node @entity1 of XXXX ].

answer: @entity3


abstract: A64 -year-old @entity0 was referred to our hospital with a diagnosis of advanced @entity2 with @entity1 to the left supraclavicular lymph nodes and paraaortic lymph nodes. Alow anterior resection was performed because of the symptoms of ileus. Subsequently, chemotherapy consisting of XELOX with bevacizumab was initiated as the first-line regimen, over 6 courses. Asecond -line regimen of FOLFIRI with bevacizumab was selected due to multiple lung @entity1 and the progression to both left supraclavicular and paraaortic lymph nodes. During the first 3 courses, the @entity0 had no harmful side effects. Although the @entity0 received adequate prophylactic antiemetic therapy and supportive treatment, grade 4 delayed @entity3 induced by irinotecan( @entity4 )occurred at 7 days after the fourth course of FOLFIRI chemotherapy. The @entity0 was given total parenteral nutrition, after which she recovered substantially from the @entity3 . Delayed @entity3 is occasionally seen with irinotecan therapy and can be efficiently managed with adequate prophylactic antiemetic therapy. However, delayed @entity3 occurring one week after administration is rarely observed. Delayed @entity3 and subsequent therapy affect the quality of life(QOL)of the @entity0 and subsequent therapy therefore, adequate attention and prompt management are required for delayed @entity3 .

title: [A Case of Advanced XXXX with Irinotecan( @entity4 )-Induced Delayed Emesis].

answer: @entity2


abstract: A64 -year-old @entity0 was referred to our hospital with a diagnosis of advanced @entity2 with @entity1 to the left supraclavicular lymph nodes and paraaortic lymph nodes. Alow anterior resection was performed because of the symptoms of ileus. Subsequently, chemotherapy consisting of XELOX with bevacizumab was initiated as the first-line regimen, over 6 courses. Asecond -line regimen of FOLFIRI with bevacizumab was selected due to multiple lung @entity1 and the progression to both left supraclavicular and paraaortic lymph nodes. During the first 3 courses, the @entity0 had no harmful side effects. Although the @entity0 received adequate prophylactic antiemetic therapy and supportive treatment, grade 4 delayed @entity3 induced by irinotecan( @entity4 )occurred at 7 days after the fourth course of FOLFIRI chemotherapy. The @entity0 was given total parenteral nutrition, after which she recovered substantially from the @entity3 . Delayed @entity3 is occasionally seen with irinotecan therapy and can be efficiently managed with adequate prophylactic antiemetic therapy. However, delayed @entity3 occurring one week after administration is rarely observed. Delayed @entity3 and subsequent therapy affect the quality of life(QOL)of the @entity0 and subsequent therapy therefore, adequate attention and prompt management are required for delayed @entity3 .

title: [A Case of Advanced @entity2 with Irinotecan( XXXX )-Induced Delayed Emesis].

answer: @entity4


abstract: A 53-years-old @entity1 was diagnosed with left @entity0 (T2N0M0, Stage IIA)and underwent breast conserving surgeryand axillaryly mph nodes resection. She was administered 2 courses of chemotherapyconsisting of cyclophosphamide, methotrexate, and fluorouracil(CMF)and received a total of 50 Gyof radiation therapyas adjuvant therapy. Ultrasonographyof the right breast, performed 2 years after the first operation, detected a @entity2 7mm in diameter. A core needle biopsy of the @entity2 was performed. The pathological diagnosis was @entity4 . The @entity1 's whole bodywas checked for metastatic legions, but none were found. Right axillary lymph node swelling was detected 9 years after her first operation, and a surgical biopsywas performed. Frozen section analysis indicated that it was metastasis from the @entity0 . A further surgical biopsywas performed on the right breast mass. Frozen section analysis indicated the @entity2 was @entity3 within a @entity4 . Breast conserving surgeryand axillaryly mph node dissection were performed for the right @entity0 . The final permanent pathological diagnosis of the right breast was @entity3 within @entity4 ( T2N1M0, Stage IIB), negative for @entity6 , negative for @entity7 , and negative for @entity5 ( @entity5 ). The @entity1 was administered 3 courses of chemotherapyconsisting of taxotere and cyclophosphamide(TC)and received a total of 50 Gy of radiation therapy. The @entity1 is alive without metastases 3 years after the second surgery.

title: [A difficult diagnosis of asynchronous both side XXXX ].

answer: @entity0


abstract: BACKGROUND Stress can cause psychological and physiological changes. Many studies revealed that massage can decrease stress. However, @entity5 has not been well researched in this regard. The purpose of this study was to investigate the immediate effects of @entity5 ( @entity5 ) on @entity4 levels (sAA), @entity3 (ANS) function, and plasma @entity1 activity (PRA). MATERIAL AND METHODS Twenty-nine healthy @entity0 were randomly allocated into either a @entity5 ( @entity5 ) group or Control (C) group, after which they were switched to the other group with a 2-week wash-out period. Each of them was given a 10-minute mental arithmetic test to induce @entity2 before a 1-hour session of @entity5 or rest. RESULTS Within-groups comparison revealed that sAA was significantly decreased (p<0.05) in the @entity5 group but not in the C group. HRV and ANS function were significantly increased (p<0.05) and PRA was significantly decreased (p<0.05) in both groups. However, low frequency per high frequency ratio (LF/HF ratio) and ANS balance status were not changed. Only sAA was found to be significantly different between groups (p<0.05). CONCLUSIONS We conclude that both @entity5 and rest can reduce @entity2 , as indicated by decreased sAA levels, increased parasympathetic activity, decreased sympathetic activity, and decreased PRA. However, @entity5 may have a modest effect on stress reduction as indicated by a reduced sAA.

title: Immediate Effects of Traditional Thai Massage on Psychological Stress as Indicated by XXXX Levels in Healthy @entity0 .

answer: @entity4


abstract: BACKGROUND Stress can cause psychological and physiological changes. Many studies revealed that massage can decrease stress. However, @entity5 has not been well researched in this regard. The purpose of this study was to investigate the immediate effects of @entity5 ( @entity5 ) on @entity4 levels (sAA), @entity3 (ANS) function, and plasma @entity1 activity (PRA). MATERIAL AND METHODS Twenty-nine healthy @entity0 were randomly allocated into either a @entity5 ( @entity5 ) group or Control (C) group, after which they were switched to the other group with a 2-week wash-out period. Each of them was given a 10-minute mental arithmetic test to induce @entity2 before a 1-hour session of @entity5 or rest. RESULTS Within-groups comparison revealed that sAA was significantly decreased (p<0.05) in the @entity5 group but not in the C group. HRV and ANS function were significantly increased (p<0.05) and PRA was significantly decreased (p<0.05) in both groups. However, low frequency per high frequency ratio (LF/HF ratio) and ANS balance status were not changed. Only sAA was found to be significantly different between groups (p<0.05). CONCLUSIONS We conclude that both @entity5 and rest can reduce @entity2 , as indicated by decreased sAA levels, increased parasympathetic activity, decreased sympathetic activity, and decreased PRA. However, @entity5 may have a modest effect on stress reduction as indicated by a reduced sAA.

title: Immediate Effects of Traditional Thai Massage on Psychological Stress as Indicated by @entity4 Levels in Healthy XXXX .

answer: @entity0


abstract: BACKGROUND: @entity2 ( @entity2 ) in young adults is a rare but devastating illness with significant socioeconomic implications, and studies of this @entity0 subgroup are limited. AIM: This study employed the National Lung Cancer Audit to compare the clinical features and survival of young adults with @entity2 with the older age groups. DESIGN: A retrospective cohort review using a validated national audit dataset. METHODS: Data were analysed for the period between 1 January 2004 and 31 December 2011. Young adults were defined as between 18 and 39 years, and all others were divided into decade age groups, up to the 80 years and above group. We performed logistic and Cox regression analyses to assess clinical outcomes. RESULTS: Of a total of 1 46 422 @entity0 , 651 (0.5%) were young adults, of whom a higher proportion had @entity1 (48%) than in any other age group. Stage distribution of @entity2 was similar across the age groups and 71% of young @entity0 had stage IIIb/IV. Performance status (PS) was 0-1 for 85%. Young adults were more likely to have surgery and chemotherapy compared with the older age groups and had better overall and post-operative survival. The proportion with @entity1 , better PS and that receiving surgery or chemotherapy diminished progressively with advancing decade age groups. CONCLUSION: In our cohort of young adults with @entity2 , the majority had good PS despite the same late-stage disease as older @entity0 . They were more likely to have treatment and survive longer than older @entity0 .

title: XXXX in young adults: presentation and survival in the English National Lung Cancer Audit.

answer: @entity2


abstract: OBJECTIVE: To summarize and analyze the clinical characteristics of Mondini @entity3 with @entity5 , as well as preliminarily investigate the genetic mechanism of the disease. METHOD: The clinical data of 2 @entity0 diagnosed as Mondini @entity3 with @entity5 treated in our hospital were analyzed. Blood samples of these two @entity0 were obtained to extract DNA. We screened DNA samples for gene @entity6 mutations by using polymerase chain reaction and direct sequencing. The sequencing results were analyzed in DNASTAR software. RESULT: Both @entity0 came to our hospital because of @entity2 , and the @entity1 were both located in vestibular window. @entity0 were cured one-time after surgical closure of the leakages with temporalis + temporalis fascia + temporalis through the mastoid approach. No pathogenic mutations of gene @entity6 with exome sequencing were found. CONCLUSION: Mondini @entity3 with @entity5 should be considered in @entity0 with @entity2 and @entity4 . Temporal bone HRCT is helpful to the diagnosis. Surgical closure is an effective therapeutic method and may prevent @entity2 . The molecular mechanism of simple Mondini @entity3 needs further study.

title: [Clinical analysis of Mondini XXXX with @entity5 and preliminary genetic research of it].

answer: @entity3


abstract: OBJECTIVE: To summarize and analyze the clinical characteristics of Mondini @entity3 with @entity5 , as well as preliminarily investigate the genetic mechanism of the disease. METHOD: The clinical data of 2 @entity0 diagnosed as Mondini @entity3 with @entity5 treated in our hospital were analyzed. Blood samples of these two @entity0 were obtained to extract DNA. We screened DNA samples for gene @entity6 mutations by using polymerase chain reaction and direct sequencing. The sequencing results were analyzed in DNASTAR software. RESULT: Both @entity0 came to our hospital because of @entity2 , and the @entity1 were both located in vestibular window. @entity0 were cured one-time after surgical closure of the leakages with temporalis + temporalis fascia + temporalis through the mastoid approach. No pathogenic mutations of gene @entity6 with exome sequencing were found. CONCLUSION: Mondini @entity3 with @entity5 should be considered in @entity0 with @entity2 and @entity4 . Temporal bone HRCT is helpful to the diagnosis. Surgical closure is an effective therapeutic method and may prevent @entity2 . The molecular mechanism of simple Mondini @entity3 needs further study.

title: [Clinical analysis of Mondini @entity3 with XXXX and preliminary genetic research of it].

answer: @entity5


abstract: UNASSIGNED: @entity4 ( @entity4 ) is a risk factor for @entity8 and @entity1 during growth and adulthood. However, this risk might be modulated by environmental factors during development. Here we examined whether exposing adolescent male and female @entity0 with @entity7 -induced @entity4 to @entity10 ( @entity10 ) affected their working memory and @entity3 -like behavior in adulthood. We also used @entity5 staining to investigate hippocampal cellular proliferation and @entity5 and @entity6 double staining to investigate neural differentiation in female @entity4 @entity0 . In the absence of adolescent stress, @entity4 female @entity0 , but not male @entity0 , scored significantly lower in the T-maze test of working memory and exhibited higher @entity3 -like behavior in the elevated-plus maze test compared with controls. Adolescent exposure to @entity10 abolished these @entity2 in @entity4 females. In the absence of adolescent stress, hippocampal cellular proliferation was significantly higher in @entity4 females than in non- @entity4 female controls and was not influenced by adolescent exposure to @entity10 . Hippocampal neural differentiation was equivalent in non-stressed control and @entity4 females. Neural differentiation was significantly increased by adolescent exposure to @entity10 in controls but not in @entity4 females. There was no significant difference in the serum @entity9 concentrations between non-stressed control and @entity4 females; however, adolescent exposure to @entity10 significantly increased serum @entity9 concentration in control females but not in @entity4 females. These results demonstrate that adolescent exposure to @entity10 improves @entity2 independent of hippocampal neurogenesis in adult @entity0 with @entity4 .

title: Exposure to @entity10 in adolescence improves the working memory and XXXX -like behavior of adult female @entity0 with intrauterine growth restriction, independently of hippocampal neurogenesis.

answer: @entity3


abstract: UNASSIGNED: @entity4 ( @entity4 ) is a risk factor for @entity8 and @entity1 during growth and adulthood. However, this risk might be modulated by environmental factors during development. Here we examined whether exposing adolescent male and female @entity0 with @entity7 -induced @entity4 to @entity10 ( @entity10 ) affected their working memory and @entity3 -like behavior in adulthood. We also used @entity5 staining to investigate hippocampal cellular proliferation and @entity5 and @entity6 double staining to investigate neural differentiation in female @entity4 @entity0 . In the absence of adolescent stress, @entity4 female @entity0 , but not male @entity0 , scored significantly lower in the T-maze test of working memory and exhibited higher @entity3 -like behavior in the elevated-plus maze test compared with controls. Adolescent exposure to @entity10 abolished these @entity2 in @entity4 females. In the absence of adolescent stress, hippocampal cellular proliferation was significantly higher in @entity4 females than in non- @entity4 female controls and was not influenced by adolescent exposure to @entity10 . Hippocampal neural differentiation was equivalent in non-stressed control and @entity4 females. Neural differentiation was significantly increased by adolescent exposure to @entity10 in controls but not in @entity4 females. There was no significant difference in the serum @entity9 concentrations between non-stressed control and @entity4 females; however, adolescent exposure to @entity10 significantly increased serum @entity9 concentration in control females but not in @entity4 females. These results demonstrate that adolescent exposure to @entity10 improves @entity2 independent of hippocampal neurogenesis in adult @entity0 with @entity4 .

title: Exposure to XXXX in adolescence improves the working memory and @entity3 -like behavior of adult female @entity0 with intrauterine growth restriction, independently of hippocampal neurogenesis.

answer: @entity10


abstract: UNASSIGNED: @entity4 ( @entity4 ) is a risk factor for @entity8 and @entity1 during growth and adulthood. However, this risk might be modulated by environmental factors during development. Here we examined whether exposing adolescent male and female @entity0 with @entity7 -induced @entity4 to @entity10 ( @entity10 ) affected their working memory and @entity3 -like behavior in adulthood. We also used @entity5 staining to investigate hippocampal cellular proliferation and @entity5 and @entity6 double staining to investigate neural differentiation in female @entity4 @entity0 . In the absence of adolescent stress, @entity4 female @entity0 , but not male @entity0 , scored significantly lower in the T-maze test of working memory and exhibited higher @entity3 -like behavior in the elevated-plus maze test compared with controls. Adolescent exposure to @entity10 abolished these @entity2 in @entity4 females. In the absence of adolescent stress, hippocampal cellular proliferation was significantly higher in @entity4 females than in non- @entity4 female controls and was not influenced by adolescent exposure to @entity10 . Hippocampal neural differentiation was equivalent in non-stressed control and @entity4 females. Neural differentiation was significantly increased by adolescent exposure to @entity10 in controls but not in @entity4 females. There was no significant difference in the serum @entity9 concentrations between non-stressed control and @entity4 females; however, adolescent exposure to @entity10 significantly increased serum @entity9 concentration in control females but not in @entity4 females. These results demonstrate that adolescent exposure to @entity10 improves @entity2 independent of hippocampal neurogenesis in adult @entity0 with @entity4 .

title: Exposure to @entity10 in adolescence improves the working memory and @entity3 -like behavior of adult female XXXX with intrauterine growth restriction, independently of hippocampal neurogenesis.

answer: @entity0


abstract: We report on 2 @entity0 with @entity3 who underwent surgicalresection for localrecurrence after gastrectomy. @entity0 1 was admitted to our hospitalbecause of @entity5 caused by localrecurrence with abdominalwal l invasion. He had undergone distalgastrectomy for @entity3 2 years and 4 months previously. Surgicalresection of the @entity1 involving the stomach-jejunum @entity2 region with partialhepatectomy and colectomy was performed. The @entity0 was subsequently discharged without symptoms. A re-recurrence requiring ileocolic bypass then occurred. In spite of chemotherapy and radiotherapy, he died 6 months after the re-recurrence. @entity0 2 was admitted to our hospitalbecause of ileus by transverse @entity4 . He had undergone total gastrectomy for @entity3 6 years and 7 months previously and received chemotherapy for local recurrence 4 years after the first surgery. Resection of the local recurrence involving the right transverse colon and the gallbladder was performed at that time. He was discharged without symptoms. He exhibited rerecurrence in the right-upper abdomen 2 months after the second operation. Surgicalresection for localrecurrence is useful for the improvement of quality of life(QOL)in appropriate cases, but the re-recurrence risk is high because of low curability in these cases.

title: [Significance of surgical resection of local recurrence after gastrectomy for XXXX - report of two cases].

answer: @entity3


abstract: Amale @entity0 in his 40s presented with @entity3 and mass palpitation. He was diagnosed with a submucosal @entity2 and referred to our clinic. Computed topography(CT)scan revealed a large @entity2 and multiple hepatic metastases. He was diagnosed with unresectable @entity4 ( @entity5 )and began @entity7 treatment. However, 2 weeks later, the @entity0 developed a high fever and @entity3 . Tumor @entity1 and @entity6 formation was observed on the CT scan. We performed emergency surgery, which comprised partial gastrectomy, distal pancreatectomy, and splenectomy, combined with radiofrequency ablation(RFA)for the hepatic metastases. Subsequently, he continued @entity7 therapy. However, a new lesion developed in the liver and was diagnosed as @entity7 -resistant disease. The new lesion was treated with RFA. Eight years after the treatment, a new lesion occurred in the liver, which was difficult to excise owing to the location. Accordingly, a right-hepatic lobectomy was performed. Currently, he is alive and continues on @entity7 therapy.

title: [A Case of Giant XXXX with Multiple Hepatic Metastases with Long-Term Survival after Multimodal Therapy].

answer: @entity2


abstract: @entity4 (ESS) is an immunologically well defined cytoplasmic antigen of group A and some group C streptococci. ESS is probably the pathogenetic @entity2 ( @entity2 ). Antibodies to ESS (ESS-Ab) were determined by microcomplement fixation in 1,102 @entity0 and by ELISA in 105 @entity0 . In 168 @entity0 with @entity2 (90 from the U.S.A. and 78 from Kuwait) the arithmetic mean titer was 45.2 (log10 1.40 +/- 0.606) and 50.2 (log10 1.51 +/- 0.394) respectively, both significantly elevated compared to 347 age matched @entity0 and adults from the U.S.A. whose arithmetic mean titer was 9.1 (log10 0.83 +/- 0.635) and 7.5 (log10 0.55 +/- 0.492) respectively and 139 @entity0 from Kuwait whose arithmetic mean titer was 15.7 (log10 0.92 +/- 0.495). In 51 @entity0 with @entity2 , the mean ELISA value was 67.5% higher than the values obtained from 54 normal age matched controls. @entity0 with @entity3 without renal involvement had only transiently and mildly elevated values. ESS-Abs in @entity0 with other types of @entity2 were in the range of normal. ESS-Ab titers do not parallel the titers of streptococcal exoenzymes. ESS-Ab titers are of importance for the differential diagnosis of @entity1 and of similar significance for the understanding of the pathogenetic mechanism of @entity2 . They are possibly of significance for therapy in the form of an active vaccine.

title: Significance of endostreptosin antibody titers in poststreptococcal XXXX .

answer: @entity2


abstract: BACKGROUND: @entity3 ( @entity3 ), @entity5 and @entity2 can occur as an early and late complication of @entity1 in the clinical course. @entity1 @entity0 are at increased risk for @entity3 from direct and indirect effects of their malignancy. AIMS: The aim of our study was to evaluate the relationship between @entity1 and the long-term outcome, mortality and the presence of @entity4 in @entity0 with acute @entity3 treated with i.v. thrombolysis. METHODS: We retrospectively evaluated the demographic and clinical data of 495 Caucasian @entity0 with acute @entity3 and 40 @entity0 with @entity3 and concomitant @entity1 who were consecutively treated from 2006 to 2013 in two experienced @entity3 centres. RESULTS: In analysed group, there were 7.8% of @entity0 with @entity1 [50.0% male, mean age 72.3      9.3; National Institutes of Health @entity3 Scale - 13 (range 9.5-17)]. @entity1 was diagnosed before i.v.-thrombolysis in 28 (70.0%) @entity0 . After 3  months of follow up, 60% of @entity0 were independent (mRS 0-2) compared with the group of @entity0 without @entity1 - 55% (p  =  0.54), 17.5% died (18.4%; p  =  0.89), 12.4% suffered @entity4 ( @entity4 ) (17.6%; p  =  0.41) and 2.5% experienced SICH (4.4%; p  =  0.56, respectively). Other clinical complications were not found. A multivariate analysis showed no impact of @entity1 on unfavourable outcomes [modified Rankin scale 3-6)] after 3 months (p  =  0.15). CONCLUSION: Intravenous thrombolysis performed in Caucasian @entity3 @entity0 with past or current @entity1 , but not in the course of chemo- and radiotherapy, can be a safe and effective method of treatment. In making decision on the thrombolytic treatment, the risk of @entity4 complications and the life expectancy should be assessed.

title: Safety of intravenous thrombolysis for acute XXXX including concomitant @entity1 sufferers - experience from Poland.

answer: @entity3


abstract: BACKGROUND: @entity3 ( @entity3 ), @entity5 and @entity2 can occur as an early and late complication of @entity1 in the clinical course. @entity1 @entity0 are at increased risk for @entity3 from direct and indirect effects of their malignancy. AIMS: The aim of our study was to evaluate the relationship between @entity1 and the long-term outcome, mortality and the presence of @entity4 in @entity0 with acute @entity3 treated with i.v. thrombolysis. METHODS: We retrospectively evaluated the demographic and clinical data of 495 Caucasian @entity0 with acute @entity3 and 40 @entity0 with @entity3 and concomitant @entity1 who were consecutively treated from 2006 to 2013 in two experienced @entity3 centres. RESULTS: In analysed group, there were 7.8% of @entity0 with @entity1 [50.0% male, mean age 72.3      9.3; National Institutes of Health @entity3 Scale - 13 (range 9.5-17)]. @entity1 was diagnosed before i.v.-thrombolysis in 28 (70.0%) @entity0 . After 3  months of follow up, 60% of @entity0 were independent (mRS 0-2) compared with the group of @entity0 without @entity1 - 55% (p  =  0.54), 17.5% died (18.4%; p  =  0.89), 12.4% suffered @entity4 ( @entity4 ) (17.6%; p  =  0.41) and 2.5% experienced SICH (4.4%; p  =  0.56, respectively). Other clinical complications were not found. A multivariate analysis showed no impact of @entity1 on unfavourable outcomes [modified Rankin scale 3-6)] after 3 months (p  =  0.15). CONCLUSION: Intravenous thrombolysis performed in Caucasian @entity3 @entity0 with past or current @entity1 , but not in the course of chemo- and radiotherapy, can be a safe and effective method of treatment. In making decision on the thrombolytic treatment, the risk of @entity4 complications and the life expectancy should be assessed.

title: Safety of intravenous thrombolysis for acute @entity3 including concomitant XXXX sufferers - experience from Poland.

answer: @entity1


abstract: UNASSIGNED: Background: @entity2 is a common complication associated with @entity1 and is marked by poor health and increased risk of morbidity and mortality. There are ongoing concerns with the use of @entity3 Stimulating Agents (ESAs) to treat @entity2 in @entity0 with @entity1 on dialysis. Questions as to their benefits, harms and overall effect on quality of life are still relevant today. Our objective was to systematically review studies evaluating the cost-effectiveness of ESAs in @entity0 with @entity1 on dialysis. Methods: We performed a systematic review of studies determining the cost-effectiveness of ESAs in adult @entity0 on dialysis. Databases, including PubMed, EMBASE, and Cochrane Database of Systematic Reviews, were searched from their establishment until June 2013. Studies that reported an incremental cost-effectiveness ratio of hemoglobin correction strategies based on ESA treatments in comparison to red blood cell transfusions, lower hemoglobin targets, or no ESA treatment were included. Results: Seven studies met inclusion criteria. Reported cost/quality-adjusted life-year (QALY) ratios ranged from USD 931-677,749/QALY across five studies comparing ESAs to red blood cell transfusions. There was heterogeneity in results when considering higher hemoglobin targets, with studies finding higher targets to be both dominant and dominated. Mortality, hospitalization, and utility estimates were major drivers. Conclusions: There is substantial variability in the estimates of the cost-effectiveness of using ESAs in the dialysis population. New models incorporating recent meta-analyses for estimates of utility, mortality, and hospitalization changes would allow for a more comprehensive answer to this question.    2015 S. Karger AG, Basel.

title: The Cost Effectiveness of XXXX -Stimulating Agents for Treating @entity2 in @entity0 on Dialysis: A Systematic Review.

answer: @entity3


abstract: UNASSIGNED: Background: @entity2 is a common complication associated with @entity1 and is marked by poor health and increased risk of morbidity and mortality. There are ongoing concerns with the use of @entity3 Stimulating Agents (ESAs) to treat @entity2 in @entity0 with @entity1 on dialysis. Questions as to their benefits, harms and overall effect on quality of life are still relevant today. Our objective was to systematically review studies evaluating the cost-effectiveness of ESAs in @entity0 with @entity1 on dialysis. Methods: We performed a systematic review of studies determining the cost-effectiveness of ESAs in adult @entity0 on dialysis. Databases, including PubMed, EMBASE, and Cochrane Database of Systematic Reviews, were searched from their establishment until June 2013. Studies that reported an incremental cost-effectiveness ratio of hemoglobin correction strategies based on ESA treatments in comparison to red blood cell transfusions, lower hemoglobin targets, or no ESA treatment were included. Results: Seven studies met inclusion criteria. Reported cost/quality-adjusted life-year (QALY) ratios ranged from USD 931-677,749/QALY across five studies comparing ESAs to red blood cell transfusions. There was heterogeneity in results when considering higher hemoglobin targets, with studies finding higher targets to be both dominant and dominated. Mortality, hospitalization, and utility estimates were major drivers. Conclusions: There is substantial variability in the estimates of the cost-effectiveness of using ESAs in the dialysis population. New models incorporating recent meta-analyses for estimates of utility, mortality, and hospitalization changes would allow for a more comprehensive answer to this question.    2015 S. Karger AG, Basel.

title: The Cost Effectiveness of @entity3 -Stimulating Agents for Treating XXXX in @entity0 on Dialysis: A Systematic Review.

answer: @entity2


abstract: UNASSIGNED: Background: @entity2 is a common complication associated with @entity1 and is marked by poor health and increased risk of morbidity and mortality. There are ongoing concerns with the use of @entity3 Stimulating Agents (ESAs) to treat @entity2 in @entity0 with @entity1 on dialysis. Questions as to their benefits, harms and overall effect on quality of life are still relevant today. Our objective was to systematically review studies evaluating the cost-effectiveness of ESAs in @entity0 with @entity1 on dialysis. Methods: We performed a systematic review of studies determining the cost-effectiveness of ESAs in adult @entity0 on dialysis. Databases, including PubMed, EMBASE, and Cochrane Database of Systematic Reviews, were searched from their establishment until June 2013. Studies that reported an incremental cost-effectiveness ratio of hemoglobin correction strategies based on ESA treatments in comparison to red blood cell transfusions, lower hemoglobin targets, or no ESA treatment were included. Results: Seven studies met inclusion criteria. Reported cost/quality-adjusted life-year (QALY) ratios ranged from USD 931-677,749/QALY across five studies comparing ESAs to red blood cell transfusions. There was heterogeneity in results when considering higher hemoglobin targets, with studies finding higher targets to be both dominant and dominated. Mortality, hospitalization, and utility estimates were major drivers. Conclusions: There is substantial variability in the estimates of the cost-effectiveness of using ESAs in the dialysis population. New models incorporating recent meta-analyses for estimates of utility, mortality, and hospitalization changes would allow for a more comprehensive answer to this question.    2015 S. Karger AG, Basel.

title: The Cost Effectiveness of @entity3 -Stimulating Agents for Treating @entity2 in XXXX on Dialysis: A Systematic Review.

answer: @entity0


abstract: Since 1988, the french non-governmental organisation M  decins Sans Fronti  res is running a control program of @entity0 @entity4 in the district of Moyo, North-Uganda. Between 1988 and 1993, more than 7,000 @entity0 were diagnosed and treated. Since 1988, it has been noted that incidence of @entity7 reaction had increased systematically between June and October of each year, indicating strong seasonal variation. In 1992 and 1993, two outbreaks of arsenical reactive @entity2 (ARE) occurred in the @entity1 center of Adjumani. The incidence of ARE suddenly exceeded 10% of the @entity0 treated by @entity7 during August 1992 and September 1993. The onset of 80% of those "epidemic" cases, occurred between the 5th and the 11th day of treatment. Two retrospective studies were conducted in 1992 (75 cases) and in 1993 (51 cases). Among the risk factors studied, two appear to increase the risk of ARE: the prescription of @entity6 to treat @entity5 during the @entity7 cure and the @entity3 general clinical conditions of @entity0 . These observations suggest that exogenous co-factors could be involved in the occurrence of ARE. Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of @entity0 before the cure of @entity7 .

title: [2 epidemics of arsenical XXXX in the treatment of trypanosomiasis, Uganda, 1992-1993].

answer: @entity2


abstract: AIM: To update and improve estimates of morbidity and mortality due to @entity3 consumption in New Zealand. METHOD: We applied the comparative risk assessment methods of the Global Burden of Disease Study at country level, and separately for Maori and non-Maori where possible. Analysis was restricted to 0-79 year olds. RESULTS: We estimated 5.4% of all @entity4 under 80 years old were attributable to @entity3 in 2007 (802 @entity4 ) and these represented 13,769 years of life lost (YLLs). Injuries accounted for 43%, @entity2 for 30% and other diseases for 27% of @entity4 . We also calculated 351 @entity4 were averted by @entity3 use, but only 3095 YLLs, resulting in a net annual loss of more than 10,000 years of life. Sex and ethnic disparities were marked, with twice as many @entity4 in @entity1 as @entity1 for both Maori and non- Maori, and the age-standardised @entity4 rate for Maori two and a half times the rate for non-Maori. Injury was the biggest cause of @entity3 -related @entity4 and YLLs in the young and overall, but the leading cause of @entity3 -related @entity4 in both Maori and non-Maori @entity1 was @entity0 . We estimated 6.5% of all healthy life lost among 0-79 year olds in 2004 was attributable to @entity3 (28,403 DALYs lost), and 6538 DALYs were prevented. The sex disparity in DALYs lost mirrored the mortality analysis, but no disaggregation by ethnicity was possible. CONCLUSION: @entity3 consumption results in substantial loss of good health across the life course in New Zealand. It makes an important contribution to Maori/non-Maori and male/female health disparities. High average consumption and heavy drinking occasions confer the greatest risk of harm to the drinker and others. At a population level there are no documented health benefits of drinking before middle-age and benefits in later life are increasingly uncertain.

title: The burden of disease and injury attributable to XXXX in New Zealanders under 80 years of age: marked disparities by ethnicity and sex.

answer: @entity3


abstract: BACKGROUND: @entity3 is a common nosocomial microorganism and its @entity2 's resistance has increased. The management of these cases is unclear. OBJECTIVE: We evaluated 16 @entity0 with KPC-producing @entity3 infections, detailing the site of infection, therapy, clinical and epidemiological data. METHODS: A retrospective and descriptive study. Clinical data were revised and KPC-2 detection was by molecular methods. Risk factors associated with mortality were compared using appropriate tests according to variable type with a significance level of 0.05. RESULTS: The 30-day mortality rate was 37.5% with no association with inadequate treatment. Age (p=0.004) and Charlson score of comorbidities (p=0.048) were independent risk factors associated with @entity1 in the multivariate analysis. The odds ratio for age >43 years was 3.00 (95% CI: 1.02-9.32) and for Charlson score >3 was 2.00 (95% CI: 1.08-3.71). Five strains were pan-resistant based on automated susceptibility tests. All @entity0 were treated with monotherapy. CONCLUSION: The clinician should be alert to @entity2 -resistant Enterobacteriaceae infection in older @entity0 with comorbidities. The mortality is high and we believe that prompt and adequate therapy must be employed.

title: KPC-producing XXXX infection.

answer: @entity3


abstract: Isolated @entity1 hindlimbs were perfused at 37 degrees C and constant physiological pressure (80 +/- 0.5 mmHg) while the flow rate that was allowed to freely self-adjust was monitored. Under these conditions, evidence was obtained for both alpha- and beta-adrenergic stimulation of @entity0 consumption ( @entity8 ) in contrast to constant-flow perfusion, which has only convincingly shown alpha-adrenergic stimulation of @entity8 in response to adrenergic agents. Addition of @entity2 (NE; 1-33 nM) led to an increase in @entity8 with a maximum of 29% above the basal value at 3.3 nM, even though the flow rate decreased. @entity5 (3.3-33 nM) and @entity4 (10-100 pM) also showed similar, but lesser in magnitude, vasoconstriction-associated stimulatory effects on @entity8 . @entity7 (an alpha 1-antagonist) completely reversed the NE-mediated decrease in flow rate and significantly blocked the increased @entity8 . In contrast, @entity6 (10-1,000 nM) increased both flow rate (30%) and @entity8 (32%). The @entity6 -stimulated @entity8 was not blocked by the beta 1-, beta 2-antagonist @entity3 (10 microM), although the increased flow was reversed. In the presence of @entity3 (1 or 10 microM), BRL-35135A (a beta 3-agonist) also stimulated @entity8 (18%) without significant change in flow rate. These results lend further support to the role of the alpha 1-adrenoceptor in muscle @entity8 . In addition there is evidence for the presence of a functional @entity9 as an additional subtype responsible for NE-mediated thermogenesis in the @entity1 hindlimb.

title: Constant-pressure perfusion of @entity1 hindlimb shows alpha- and beta-adrenergic stimulation of XXXX consumption.

answer: @entity0


abstract: Isolated @entity1 hindlimbs were perfused at 37 degrees C and constant physiological pressure (80 +/- 0.5 mmHg) while the flow rate that was allowed to freely self-adjust was monitored. Under these conditions, evidence was obtained for both alpha- and beta-adrenergic stimulation of @entity0 consumption ( @entity8 ) in contrast to constant-flow perfusion, which has only convincingly shown alpha-adrenergic stimulation of @entity8 in response to adrenergic agents. Addition of @entity2 (NE; 1-33 nM) led to an increase in @entity8 with a maximum of 29% above the basal value at 3.3 nM, even though the flow rate decreased. @entity5 (3.3-33 nM) and @entity4 (10-100 pM) also showed similar, but lesser in magnitude, vasoconstriction-associated stimulatory effects on @entity8 . @entity7 (an alpha 1-antagonist) completely reversed the NE-mediated decrease in flow rate and significantly blocked the increased @entity8 . In contrast, @entity6 (10-1,000 nM) increased both flow rate (30%) and @entity8 (32%). The @entity6 -stimulated @entity8 was not blocked by the beta 1-, beta 2-antagonist @entity3 (10 microM), although the increased flow was reversed. In the presence of @entity3 (1 or 10 microM), BRL-35135A (a beta 3-agonist) also stimulated @entity8 (18%) without significant change in flow rate. These results lend further support to the role of the alpha 1-adrenoceptor in muscle @entity8 . In addition there is evidence for the presence of a functional @entity9 as an additional subtype responsible for NE-mediated thermogenesis in the @entity1 hindlimb.

title: Constant-pressure perfusion of XXXX hindlimb shows alpha- and beta-adrenergic stimulation of @entity0 consumption.

answer: @entity1


abstract: BACKGROUND: The factors associated with outcome of @entity0 with nonocclusive @entity4 are poorly defined. METHODS: Over a 7-year period, 34 consecutive @entity0 with nonocclusive @entity4 were identified. RESULTS: The mean age of the study @entity0 was 63 years (range 31 to 94); 21 of 34 (62%) were @entity0 . The mean delay in diagnosis was 31 hours (range 7 hours to 6 days). Seven of 34 (21%) underwent preoperative visceral arteriography. Two of these 7 required surgery, and both died as a result of @entity3 . The remaining 27 had the diagnosis made at celiotomy. Among the 29 who were explored, 16 of 29 (55%) had @entity3 . Twenty-one of 29 (72%) had @entity1 whereas 8 of 29 (28%) had @entity1 . Among those with segmental @entity3 , primary @entity2 was performed in 12 of 21 @entity0 (57%); 5 of the 12 (42%) died. Nine of 21 @entity0 (43%) underwent delayed @entity2 ; 2 of the 9 (22%) died. No @entity0 with @entity1 underwent primary @entity2 . Second-look laparotomy was performed on 22 of 29 (76%). Eleven of those 22 (50%) had a further bowel resection. Overall, 16 of 29 (55%) who underwent surgery for nonocclusive @entity4 are alive. CONCLUSIONS: Improved survival from nonocclusive @entity4 is dependent upon the identification of high-risk groups, aggressive reexploration, and delayed intestinal @entity2 .

title: Improved outcome by identification of high-risk nonocclusive @entity4 , aggressive reexploration, and delayed XXXX .

answer: @entity2


abstract: BACKGROUND: The factors associated with outcome of @entity0 with nonocclusive @entity4 are poorly defined. METHODS: Over a 7-year period, 34 consecutive @entity0 with nonocclusive @entity4 were identified. RESULTS: The mean age of the study @entity0 was 63 years (range 31 to 94); 21 of 34 (62%) were @entity0 . The mean delay in diagnosis was 31 hours (range 7 hours to 6 days). Seven of 34 (21%) underwent preoperative visceral arteriography. Two of these 7 required surgery, and both died as a result of @entity3 . The remaining 27 had the diagnosis made at celiotomy. Among the 29 who were explored, 16 of 29 (55%) had @entity3 . Twenty-one of 29 (72%) had @entity1 whereas 8 of 29 (28%) had @entity1 . Among those with segmental @entity3 , primary @entity2 was performed in 12 of 21 @entity0 (57%); 5 of the 12 (42%) died. Nine of 21 @entity0 (43%) underwent delayed @entity2 ; 2 of the 9 (22%) died. No @entity0 with @entity1 underwent primary @entity2 . Second-look laparotomy was performed on 22 of 29 (76%). Eleven of those 22 (50%) had a further bowel resection. Overall, 16 of 29 (55%) who underwent surgery for nonocclusive @entity4 are alive. CONCLUSIONS: Improved survival from nonocclusive @entity4 is dependent upon the identification of high-risk groups, aggressive reexploration, and delayed intestinal @entity2 .

title: Improved outcome by identification of high-risk nonocclusive XXXX , aggressive reexploration, and delayed @entity2 .

answer: @entity4


abstract: BACKGROUND: The goal of this study was to determine if the outcome of antireflux surgery can be improved by: (1) conducting a careful preoperative workup to characterize @entity1 ( @entity1 ) in the individual @entity0 ; and (2) tailoring the operation to the results of the preoperative function tests. @entity0 AND METHODS: Sixty-eight @entity0 had operations for @entity1 by minimally invasive techniques. RESULTS: A Rossetti fundoplication was performed in 22 @entity0 . Sixty-eight percent became asymptomatic. Twenty-seven percent developed @entity3 or gas bloat. Thirty-five @entity0 had a Nissen fundoplication. Ninety-one percent are asymptomatic. Eleven @entity0 with severe abnormalities of esophageal peristalsis underwent a Guarner fundoplication with relief of symptoms in 82% of @entity0 . No @entity0 in the Nissen or Guarner group developed postoperative persistent @entity3 or gas bloat. A pyloromyotomy was performed in 3 @entity0 because of severe delayed @entity2 . CONCLUSIONS: Minimally invasive surgery for @entity1 gives good-to-excellent results even in @entity0 with abnormal esophageal body function, provided that the operation is tailored to the individual @entity0 based on the results of the preoperative function tests.

title: Minimally invasive surgery for XXXX .

answer: @entity1


abstract: BACKGROUND: A gradual change in the management of @entity1 has occurred at our institution. This study was therefore undertaken to determine whether changes in management of @entity1 influenced outcomes during the past 30 years. @entity0 AND METHODS: A retrospective study of @entity0 admitted with @entity1 between 1965 and 1994 was performed. Two hundred seven @entity0 were identified and demographic and outcome data were recorded. @entity0 were then grouped based upon the period in which they received treatment (ie, Period I [1965 to 1974], Period II [1975 to 1984], and Period III [1985 to 1994]), and the type of treatment received (ie, splenectomy, splenorrhaphy, or observation). RESULTS: More @entity0 were treated in Period III than in the other two periods, and Period III @entity0 had shorter hospital stays. Splenectomy was solely used during Period I; splenorrhaphy and observation were occasionally performed during Period II; and splenectomy, splenorrhaphy, and observation were performed in near-equal numbers during Period III. Mortality was similar for each period, though Injury Severity Scores (ISS) were higher during later years. When compared by treatment modality, @entity0 receiving splenectomy had higher ISS and @entity1 classifications. CONCLUSION: @entity0 treated by splenorrhaphy and observation for @entity1 have markedly increased over the past 30 years without adverse outcome.

title: Changing trends in the management of XXXX .

answer: @entity1


abstract: STUDY OBJECTIVE: To determine whether warming of @entity3 decreases the @entity0 of its injection during @entity2 . DESIGN: Prospective, randomized, double-blind, controlled trial. INTERVENTIONS: Twenty healthy volunteers received bilateral digital nerve blocks of their middle finger. They were first randomly assigned to receive either room-temperature (21 degrees C) or heated (42 degrees C) 2% @entity3 in their first block. They were then randomly assigned to receive the first block in either the right or left hand. The blocks were performed in a standardized fashion by a single physician, who was blinded to which solution was being used. The volunteers rated the @entity0 of each digital block on a 100-mm visual analog scale (VAS). Efficacy of each digital block was tested at 5 minutes. RESULTS: Heating of the @entity3 was associated with a significantly lower median @entity1 score (31.5 versus 25.0; P < .05). There was no difference in @entity0 score between the two solutions in relation to which hand was used (P = .29) or whether the injection was the first or the second (P = .37). When all factors (temperature, order, and hand) were considered in the ANOVA with respect to @entity1 score, the only significant relation found was that between the temperature of the solution and the @entity1 score (P = .028). CONCLUSION: Heating of @entity3 decreases the @entity0 of injection during @entity2 .

title: Randomized double-blind controlled trial comparing room-temperature and heated XXXX for @entity2 .

answer: @entity3


abstract: STUDY OBJECTIVE: To determine whether warming of @entity3 decreases the @entity0 of its injection during @entity2 . DESIGN: Prospective, randomized, double-blind, controlled trial. INTERVENTIONS: Twenty healthy volunteers received bilateral digital nerve blocks of their middle finger. They were first randomly assigned to receive either room-temperature (21 degrees C) or heated (42 degrees C) 2% @entity3 in their first block. They were then randomly assigned to receive the first block in either the right or left hand. The blocks were performed in a standardized fashion by a single physician, who was blinded to which solution was being used. The volunteers rated the @entity0 of each digital block on a 100-mm visual analog scale (VAS). Efficacy of each digital block was tested at 5 minutes. RESULTS: Heating of the @entity3 was associated with a significantly lower median @entity1 score (31.5 versus 25.0; P < .05). There was no difference in @entity0 score between the two solutions in relation to which hand was used (P = .29) or whether the injection was the first or the second (P = .37). When all factors (temperature, order, and hand) were considered in the ANOVA with respect to @entity1 score, the only significant relation found was that between the temperature of the solution and the @entity1 score (P = .028). CONCLUSION: Heating of @entity3 decreases the @entity0 of injection during @entity2 .

title: Randomized double-blind controlled trial comparing room-temperature and heated @entity3 for XXXX .

answer: @entity2


abstract: STUDY OBJECTIVE: To compare the analgesic effect of IM @entity4 with that of oral @entity5 in the treatment of @entity6 . DESIGN: Prospective, randomized, double-blind, controlled, parallel group clinical trial. SETTING: Two urban emergency departments. @entity0 : Twenty consecutive @entity0 who presented to the @entity3 with @entity2 . INTERVENTIONS: Each @entity0 was randomly assigned to receive in the @entity3 (1) 60 mg of IM @entity7 and oral placebo or (2) 50 mg of oral @entity5 and IM placebo. The @entity0 rated the intensity of their @entity1 on a Wong-Baker @entity1 scale (which runs from 0 to 5) before treatment and 30, 60, 90, and 120 minutes after treatment. All the @entity0 were discharged with instructions to take oral @entity5 and to complete @entity1 score cards at home at 6, 12, and 24 hours. RESULTS: The 10 @entity0 in each group were similar with regard to age, sex, race, and initial mean @entity1 score. After 2 hours, the mean @entity1 scores (+/- SD) for the @entity7 group had decreased from 4.5 +/- .71 to 1.4 +/- 1.43 (P < .05), and the mean score for the @entity5 group had decreased from 4.4 +/- .70 to 1.5 +/- 1.18 (P < .05). The difference between the two groups was not significant. At 6 hours, there was some @entity1 rebound in the @entity7 group. CONCLUSION: IM @entity7 and oral @entity5 are similar in the relief of the @entity1 of @entity6 in the @entity3 .

title: Randomized double-blind comparison of the analgesic efficacy of intramuscular @entity7 and oral XXXX in the treatment of @entity6 .

answer: @entity5


abstract: STUDY OBJECTIVE: To compare the analgesic effect of IM @entity4 with that of oral @entity5 in the treatment of @entity6 . DESIGN: Prospective, randomized, double-blind, controlled, parallel group clinical trial. SETTING: Two urban emergency departments. @entity0 : Twenty consecutive @entity0 who presented to the @entity3 with @entity2 . INTERVENTIONS: Each @entity0 was randomly assigned to receive in the @entity3 (1) 60 mg of IM @entity7 and oral placebo or (2) 50 mg of oral @entity5 and IM placebo. The @entity0 rated the intensity of their @entity1 on a Wong-Baker @entity1 scale (which runs from 0 to 5) before treatment and 30, 60, 90, and 120 minutes after treatment. All the @entity0 were discharged with instructions to take oral @entity5 and to complete @entity1 score cards at home at 6, 12, and 24 hours. RESULTS: The 10 @entity0 in each group were similar with regard to age, sex, race, and initial mean @entity1 score. After 2 hours, the mean @entity1 scores (+/- SD) for the @entity7 group had decreased from 4.5 +/- .71 to 1.4 +/- 1.43 (P < .05), and the mean score for the @entity5 group had decreased from 4.4 +/- .70 to 1.5 +/- 1.18 (P < .05). The difference between the two groups was not significant. At 6 hours, there was some @entity1 rebound in the @entity7 group. CONCLUSION: IM @entity7 and oral @entity5 are similar in the relief of the @entity1 of @entity6 in the @entity3 .

title: Randomized double-blind comparison of the analgesic efficacy of intramuscular XXXX and oral @entity5 in the treatment of @entity6 .

answer: @entity7


abstract: STUDY OBJECTIVE: To compare the analgesic effect of IM @entity4 with that of oral @entity5 in the treatment of @entity6 . DESIGN: Prospective, randomized, double-blind, controlled, parallel group clinical trial. SETTING: Two urban emergency departments. @entity0 : Twenty consecutive @entity0 who presented to the @entity3 with @entity2 . INTERVENTIONS: Each @entity0 was randomly assigned to receive in the @entity3 (1) 60 mg of IM @entity7 and oral placebo or (2) 50 mg of oral @entity5 and IM placebo. The @entity0 rated the intensity of their @entity1 on a Wong-Baker @entity1 scale (which runs from 0 to 5) before treatment and 30, 60, 90, and 120 minutes after treatment. All the @entity0 were discharged with instructions to take oral @entity5 and to complete @entity1 score cards at home at 6, 12, and 24 hours. RESULTS: The 10 @entity0 in each group were similar with regard to age, sex, race, and initial mean @entity1 score. After 2 hours, the mean @entity1 scores (+/- SD) for the @entity7 group had decreased from 4.5 +/- .71 to 1.4 +/- 1.43 (P < .05), and the mean score for the @entity5 group had decreased from 4.4 +/- .70 to 1.5 +/- 1.18 (P < .05). The difference between the two groups was not significant. At 6 hours, there was some @entity1 rebound in the @entity7 group. CONCLUSION: IM @entity7 and oral @entity5 are similar in the relief of the @entity1 of @entity6 in the @entity3 .

title: Randomized double-blind comparison of the analgesic efficacy of intramuscular @entity7 and oral @entity5 in the treatment of XXXX .

answer: @entity6


abstract: BACKGROUND: Clinical management and outcome of @entity3 can be affected by chorionicity. In @entity1 , @entity2 has been associated with dichorionic (DC) and monochorionic placentation. Studies evaluating triplet pregnancy outcomes in relation to chorionicity have been few and may not reflect contemporary antenatal and neonatal care. OBJECTIVE: The objective of this study was to compare obstetric and perinatal outcomes in DC and trichorionic (TC) @entity1 . STUDY DESIGN: We performed a retrospective cohort study of @entity1 that delivered at >= 20 weeks' gestation at 2 Chicago area hospitals from January 1999 through December 2010. Chorionicity was determined by pathology specimen. Maternal and @entity0 charts were reviewed for obstetric and perinatal outcomes. RESULTS: The study population included 159 pregnancies (477 neonates) of which 108 were TC (67.9%) and 51 were DC (32.1%). Over 94% of mothers in this study had all 3 @entity0 survive to discharge regardless of chorionicity. No difference was found in perinatal mortality rate between DC and TC triplets (3.3% vs 4.6%; P  = .3). DC triplets were significantly more likely to be very low birthweight (41.8% vs 22.2%; odds ratio, 2.2; 95% confidence interval, 1.2-4.2; P  = .02) and to deliver at <30 weeks (25.5% vs 8.3%; odds ratio, 6.1; 95% confidence interval, 1.9-19.4; P  =  .002) compared to TC triplets. Criteria for @entity4 ( @entity4 ) were present in 3 DC @entity1 (5.9%). Neonates in pregnancies complicated by @entity4 were less likely to survive 28  days as compared to neonates from DC pregnancies that were not affected by @entity4 (P  = .02) or TC neonates (P  = .02) Neonatal survival was similar in DC pregnancies not affected by @entity4 and TC pregnancies (98.6% and 96.6%; P  = .7). CONCLUSION: Although perinatal mortality did not correlate with chorionicity, DC pregnancies were more likely to deliver <30 weeks' gestational age and have very low birthweight neonates. Neonatal mortality appears to be mediated by the presence or absence of @entity4 as 28-day survival was worse in DC pregnancies complicated by @entity4 , but similar between DC pregnancies not affected by @entity4 and TC pregnancies.

title: Perinatal and obstetric outcomes of dichorionic vs trichorionic XXXX .

answer: @entity1


abstract: PURPOSE: To evaluate the long-term prevalence of @entity4 associated with the use of SmartPlugs. METHODS: This retrospective study included 42 eyes of 25 @entity2 @entity0 at our institution who received a SmartPlug insertion between 2004 and 2008. Irrigation of the lacrimal system was performed in all @entity0 prior to SmartPlug insertion to ensure the patency of the system. The median follow-up time was 7.9 (5.6-10.5) years after plug insertion. RESULTS: Six @entity0 (seven eyes) of 25 @entity0 (42 eyes) developed @entity4 . The prevalence of @entity4 per @entity0 was 24%, and the prevalence of @entity4 per SmartPlug was 16.6%. The median time from SmartPlug insertion to the onset of @entity4 was 4.7 (1.4-6.0) years. The median age of the affected @entity0 was 61.5 (36-74) years. Five of these @entity0 were @entity0 and one was @entity0 . The pathogens were identified as Actinomyces in four eyes and as @entity1 in three eyes. In five @entity0 (six eyes), the @entity4 was resolved by the application of topical antibiotics and repeated lacrimal irrigations with antibiotics and @entity3 . In one @entity0 , a canaliculotomy was necessary to cure the condition. CONCLUSIONS: The late onset of complications after SmartPlug insertion requires long-term observation to identify the majority of complications associated with SmartPlugs. In our @entity0 with a follow-up of up to 10.5   years, the use of SmartPlugs was associated with the highest prevalence of @entity4 published thus far.

title: Prevalence of XXXX after smartplug insertion during long-term follow-up.

answer: @entity4


abstract: OBJECTIVE: To determine whether common conditions in early childhood, such as @entity3 and @entity4 (mainly @entity7 ), affect height during later childhood and in adult life. DESIGN: Longitudinal follow up of subjects in the 1958 British Birth Cohort Study. Data from the birth survey and ages 7, 11, 16, and 23 were used. SUBJECTS: 12,537 subjects remaining in the study at age 23, representing 76% of the target population, cohort members still alive and resident in Britain. RESULTS: Heights of @entity0 with @entity1 , acute or @entity6 , or @entity3 /wheezy @entity5 did not differ by age 7 from those of @entity0 without such illnesses. When @entity3 was graded by severity, there was a trend (not significant) for the severe group to be shorter at ages 16 and 23. Although @entity0 with a @entity2 by age 7 were on average almost 0.5 cm shorter than @entity0 without such illnesses, this difference was reduced by half and was not significant after adjusting for maternal height, birth weight, parity, and social class at birth. However, a marked and long lasting effect was found for @entity0 with @entity4 who at age 7 were significantly shorter, by a mean of 0.77 cm. Within this group, enuretic @entity0 with a problem at age 11 were more than 1 cm shorter in adulthood, even allowing for other height related factors. CONCLUSIONS: Common childhood illnesses do not appear to affect height, either in the short or in the long term, although exceptions include @entity2 and @entity7 . The value of height as an indicator of @entity0 health status in an industrialised country such as Britain requires further reassessment.

title: @entity3 , XXXX , and @entity2 : long term impact on height.

answer: @entity7


abstract: OBJECTIVE: To determine whether common conditions in early childhood, such as @entity3 and @entity4 (mainly @entity7 ), affect height during later childhood and in adult life. DESIGN: Longitudinal follow up of subjects in the 1958 British Birth Cohort Study. Data from the birth survey and ages 7, 11, 16, and 23 were used. SUBJECTS: 12,537 subjects remaining in the study at age 23, representing 76% of the target population, cohort members still alive and resident in Britain. RESULTS: Heights of @entity0 with @entity1 , acute or @entity6 , or @entity3 /wheezy @entity5 did not differ by age 7 from those of @entity0 without such illnesses. When @entity3 was graded by severity, there was a trend (not significant) for the severe group to be shorter at ages 16 and 23. Although @entity0 with a @entity2 by age 7 were on average almost 0.5 cm shorter than @entity0 without such illnesses, this difference was reduced by half and was not significant after adjusting for maternal height, birth weight, parity, and social class at birth. However, a marked and long lasting effect was found for @entity0 with @entity4 who at age 7 were significantly shorter, by a mean of 0.77 cm. Within this group, enuretic @entity0 with a problem at age 11 were more than 1 cm shorter in adulthood, even allowing for other height related factors. CONCLUSIONS: Common childhood illnesses do not appear to affect height, either in the short or in the long term, although exceptions include @entity2 and @entity7 . The value of height as an indicator of @entity0 health status in an industrialised country such as Britain requires further reassessment.

title: @entity3 , @entity7 , and XXXX : long term impact on height.

answer: @entity2


abstract: OBJECTIVE: To determine whether common conditions in early childhood, such as @entity3 and @entity4 (mainly @entity7 ), affect height during later childhood and in adult life. DESIGN: Longitudinal follow up of subjects in the 1958 British Birth Cohort Study. Data from the birth survey and ages 7, 11, 16, and 23 were used. SUBJECTS: 12,537 subjects remaining in the study at age 23, representing 76% of the target population, cohort members still alive and resident in Britain. RESULTS: Heights of @entity0 with @entity1 , acute or @entity6 , or @entity3 /wheezy @entity5 did not differ by age 7 from those of @entity0 without such illnesses. When @entity3 was graded by severity, there was a trend (not significant) for the severe group to be shorter at ages 16 and 23. Although @entity0 with a @entity2 by age 7 were on average almost 0.5 cm shorter than @entity0 without such illnesses, this difference was reduced by half and was not significant after adjusting for maternal height, birth weight, parity, and social class at birth. However, a marked and long lasting effect was found for @entity0 with @entity4 who at age 7 were significantly shorter, by a mean of 0.77 cm. Within this group, enuretic @entity0 with a problem at age 11 were more than 1 cm shorter in adulthood, even allowing for other height related factors. CONCLUSIONS: Common childhood illnesses do not appear to affect height, either in the short or in the long term, although exceptions include @entity2 and @entity7 . The value of height as an indicator of @entity0 health status in an industrialised country such as Britain requires further reassessment.

title: XXXX , @entity7 , and @entity2 : long term impact on height.

answer: @entity3


abstract: The impact of @entity1 source variation on the physical and chemical characteristics of aerobic granular sludge and its biological nutrient ( @entity4 and @entity5 ) removal performance was investigated. Two identical sequencing batch reactors, R1 and R2, were set up. Granular biomass was cultivated to maturity using @entity2 -based synthetic wastewater. After mature granules in both reactors with simultaneous chemical @entity0 demand (COD), @entity6 and @entity5 removal capability were achieved, the feed of R2 was changed to municipal wastewater and R1 was continued on synthetic feed as control. Biological @entity5 removal was completely inhibited in R2 due to lack of readily biodegradable COD; however, the biomass maintained high @entity6 and COD removal efficiencies. The disintegration of the granules in R2 occurred during the first two weeks after the change of feed, but it did not have significant impacts on settling properties of the sludge. Re-granulation of the biomass in R2 was then observed within 30 d after granules' disintegration when the biomass acclimated to the new substrate. The granular biomass in R1 and R2 maintained a Sludge Volume Index close to 60 and 47 mL g(-1), respectively, during the experimental period. It was concluded that changing the @entity1 source from readily biodegradable @entity2 to the more complex ones present in municipal wastewater did not have significant impacts on aerobic granular sludge characteristics; it particularly did not affect its settling properties. However, sufficient readily biodegradable @entity1 would have to be provided to maintain simultaneous biological @entity3 and @entity5 removal.

title: Influence of XXXX source on nutrient removal performance and physical-chemical characteristics of aerobic granular sludge.

answer: @entity1


abstract: UNASSIGNED: Disinfection by-products are contaminants produced during drinking water disinfection. Several DBPs have been implicated in a variety of toxic effects, mainly carcinogenic and genotoxic effects. Moreover, DBPs exposure has also been associated with an increased risk of developmental effects. In this study, the developmental @entity1 and genotoxicity of 10 DBPs (four trihalomethanes [THMs], five haloacetic acids [HAAs] and sodium bromate) in the @entity3 embryo model were evaluated. Embryos exposed for 72 hours were observed for different endpoints such as growth, hatching success, @entity2 and lethality. THMs exposure resulted in adverse developmental effects and a significant reduced tail length. Two HAAs, tribromoacetic acid and dichloroacetic acid, along with sodium bromate were found to cause a significant increase in @entity2 rate. Chloroform, chlorodibromomethane and sodium bromate produced a weak induction of DNA damage to whole embryos. However, developmental effects occurred at a range of concentrations (20-100  g/mL) several orders of magnitude above the levels that can be attained in fetal blood in @entity0 exposed to chlorinated water. In conclusion, the teratogenic and genotoxic activity observed by some DBPs in @entity3 reinforce the view that there is a weak capacity of disinfection products to cause developmental effects at environmentally relevant concentrations.

title: Developmental effects and genotoxicity of 10 water disinfection by-products in XXXX .

answer: @entity3